Pharmaceuticals, Biotechnology and Life Sciences
The U.S. Food and Drug Administration approved a new indication for Astellas Pharma’s Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspension) to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurological impairment, in children ages three years and older.
Collaboration with Astellas supports advancement of Harvard biomedical research and Astellas drug discovery research in a range of therapeutic areas, Harvard said in a press release.
Seattle Genetics, and Astellas Pharma’s study met outcomes for safety and 71 Percent of patients with locally advanced or metastatic urothelial (bladder) cancer had a confirmed response, the companies presented Saturday at ESMO Congress in Barcelona.
The sale of antifungal Cresemba (isavuconazole) in the United States by Astellas Pharma, kicked off CHF 10 million (€8.84M) payment…
Actinium Pharmaceuticals and Astellas Pharma will work together to develop Actinium-225 Radio-Conjugates (ARCs) using Actinium Warhead Enabling (AWE) Platform Technology,…
Astellas Pharma and Pfizer have amended the protocol for the registrational PROSPER trial to test the efficacy and safety of Xtandi in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC).